CA2120745A1 - A combination of anti-erbb-2 monoclonal antibodies and method of using - Google Patents
A combination of anti-erbb-2 monoclonal antibodies and method of usingInfo
- Publication number
- CA2120745A1 CA2120745A1 CA002120745A CA2120745A CA2120745A1 CA 2120745 A1 CA2120745 A1 CA 2120745A1 CA 002120745 A CA002120745 A CA 002120745A CA 2120745 A CA2120745 A CA 2120745A CA 2120745 A1 CA2120745 A1 CA 2120745A1
- Authority
- CA
- Canada
- Prior art keywords
- antibodies
- antibody
- combination
- erbb
- gene product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90655592A | 1992-06-30 | 1992-06-30 | |
US07/906,555 | 1992-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2120745A1 true CA2120745A1 (en) | 1994-01-06 |
Family
ID=25422648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002120745A Abandoned CA2120745A1 (en) | 1992-06-30 | 1992-10-21 | A combination of anti-erbb-2 monoclonal antibodies and method of using |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0655924A4 (ja) |
JP (1) | JPH08504172A (ja) |
KR (1) | KR100269879B1 (ja) |
AU (1) | AU687346B2 (ja) |
CA (1) | CA2120745A1 (ja) |
WO (1) | WO1994000136A1 (ja) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6733752B1 (en) | 1994-03-30 | 2004-05-11 | The Trustees Of The University Of Pennsylvania | Prevention of tumors with monoclonal antibodies against neu |
US5759776A (en) * | 1995-06-05 | 1998-06-02 | California Pacific Medical Center | Targets for breast cancer diagnosis and treatment |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
EP1947119A3 (en) | 1997-12-12 | 2012-12-19 | Genentech, Inc. | Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent |
EP1941905A1 (en) | 1998-03-27 | 2008-07-09 | Genentech, Inc. | APO-2 Ligand-anti-her-2 antibody synergism |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
EP2283867B1 (en) | 1999-06-25 | 2014-05-21 | ImmunoGen, Inc. | Methods of treatment using anti-ERBB antibody-maytansinoid conjugates |
CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
TR200200472T2 (tr) | 1999-08-27 | 2002-06-21 | Genentech, Inc. | Anti-Erb B2 antikorları ile tedavi için dozajlar |
CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
US20030152572A1 (en) * | 2000-04-06 | 2003-08-14 | Yoshimi Homma | Diagnostic and therapeutic agents for rheumatoid arthritis |
SI2857516T1 (sl) | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalentna protitelesa in njihove uporabe |
CN102698265A (zh) | 2000-05-19 | 2012-10-03 | 杰南技术公司 | 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
SI1501856T1 (sl) | 2002-04-10 | 2013-04-30 | Genentech, Inc. | Variante protitelesa proti HER2 |
US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
PT2263691E (pt) | 2002-07-15 | 2012-11-12 | Hoffmann La Roche | Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4) |
CN100408097C (zh) * | 2002-10-10 | 2008-08-06 | 默克专利有限公司 | 双特异性抗erb-b抗体及其在肿瘤治疗中的用途 |
SI1549344T1 (sl) * | 2002-10-10 | 2015-05-29 | Merck Patent Gmbh | FARMACEVTSKI SESTAVKI PROTI RECEPTORJEM ErbB1 |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
EP1737489B1 (en) | 2004-04-08 | 2012-01-11 | David B Agus | ErbB2 antagonists for tumor pain therapy |
KR20180091967A (ko) | 2004-07-22 | 2018-08-16 | 제넨테크, 인크. | Her2 항체 조성물 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
KR20170134771A (ko) | 2005-01-21 | 2017-12-06 | 제넨테크, 인크. | Her 항체의 고정 용량 투여법 |
KR101253576B1 (ko) | 2005-02-23 | 2013-04-11 | 제넨테크, 인크. | Her 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장 |
SI2511301T1 (en) | 2006-08-04 | 2018-05-31 | MedImmune Limited, | Human antibodies to ERBB 2 |
JP5726417B2 (ja) | 2007-03-01 | 2015-06-03 | シムフォゲン・アクティーゼルスカブSymphogen A/S | 組み換え抗上皮成長因子受容体抗体組成物 |
EP2899541A1 (en) | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Predicting response to a HER dimerisation inhbitor based on low HER3 expression |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
PL2171090T3 (pl) | 2007-06-08 | 2013-09-30 | Genentech Inc | Markery ekspresji genów odporności guza na leczenie hamujące HER2 |
PL3327026T3 (pl) | 2007-07-09 | 2020-02-28 | Genentech, Inc. | Zapobieganie redukcji wiązań disiarczkowych podczas rekombinacyjnego wytwarzania polipeptydów |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
CA2732856C (en) | 2008-08-29 | 2018-08-28 | Symphogen A/S | Cancer treatment with a combination of two different anti-epidermal growth factor receptor antibodies |
AR075896A1 (es) | 2009-03-20 | 2011-05-04 | Genentech Inc | Anticuerpos anti-her (factor de crecimiento epidermico) |
SG10201507044PA (en) | 2009-05-29 | 2015-10-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
KR101822205B1 (ko) | 2009-08-11 | 2018-01-25 | 제넨테크, 인크. | 글루타민-비함유 세포 배양 배지에서의 단백질의 생성 |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
AU2011239583A1 (en) | 2010-04-15 | 2012-11-29 | Alper Biotech, Llc | Monoclonal antibodies against HER2 antigens, and uses therefor |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
RU2586515C2 (ru) | 2010-12-21 | 2016-06-10 | Ф.Хоффманн-Ля Рош Аг | Препарат антитела, обогащенного изоформами и способ его получения |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
JP6297490B2 (ja) | 2011-08-31 | 2018-03-20 | ジェネンテック, インコーポレイテッド | 診断マーカー |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
EP2788500A1 (en) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
KR20210090298A (ko) | 2012-10-30 | 2021-07-19 | 에스퍼란스 파마슈티컬스, 인코포레이티드 | 항체/약물 컨쥬게이트 및 이의 사용 방법 |
KR102291355B1 (ko) | 2012-11-30 | 2021-08-19 | 에프. 호프만-라 로슈 아게 | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 |
KR101453462B1 (ko) | 2013-05-16 | 2014-10-23 | 앱클론(주) | Her2에 특이적으로 결합하는 항체 |
CA2943299A1 (en) | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Bispecific her2 antibodies |
EP3131584B1 (en) | 2014-04-16 | 2022-01-12 | Biocon Limited | Stable protein formulations comprising a molar excess of sorbitol |
IL292708B1 (en) | 2015-05-30 | 2024-04-01 | Molecular Templates Inc | Vaccine-free Shiga toxin A subunit scaffolds and cell-targeting molecules containing them |
AU2016280159A1 (en) | 2015-06-17 | 2017-12-07 | Genentech, Inc. | Anti-HER2 antibodies and methods of use |
JP7386796B2 (ja) | 2017-11-14 | 2023-11-27 | グリーン クロス ラボ セル コーポレーション | 抗-her2抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体 |
US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
CA3097178A1 (en) | 2018-04-17 | 2019-10-24 | Molecular Templates, Inc. | Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds |
EP3560945A1 (en) | 2018-04-27 | 2019-10-30 | F. Hoffmann-La Roche AG | Methods for purification of polypeptides using polysorbates |
JP2022532812A (ja) * | 2018-08-16 | 2022-07-20 | カンタージア アクチエボラーグ | 抗il1rap抗体組成物 |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4867962A (en) * | 1988-02-26 | 1989-09-19 | Neorx Corporation | Functionally specific antibodies |
EP0494135B1 (en) * | 1989-09-29 | 1996-04-10 | Oncogene Science, Inc. | Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human |
-
1992
- 1992-10-21 CA CA002120745A patent/CA2120745A1/en not_active Abandoned
- 1992-10-21 EP EP93906955A patent/EP0655924A4/en not_active Withdrawn
- 1992-10-21 JP JP6502307A patent/JPH08504172A/ja not_active Ceased
- 1992-10-21 WO PCT/US1992/008545 patent/WO1994000136A1/en not_active Application Discontinuation
- 1992-10-21 AU AU37733/93A patent/AU687346B2/en not_active Ceased
- 1992-10-21 KR KR1019940701148A patent/KR100269879B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR950700075A (ko) | 1995-01-16 |
AU687346B2 (en) | 1998-02-26 |
WO1994000136A1 (en) | 1994-01-06 |
EP0655924A4 (en) | 1996-09-11 |
KR100269879B1 (ko) | 2000-10-16 |
EP0655924A1 (en) | 1995-06-07 |
AU3773393A (en) | 1994-01-24 |
JPH08504172A (ja) | 1996-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2120745A1 (en) | A combination of anti-erbb-2 monoclonal antibodies and method of using | |
Fendly et al. | Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product | |
JP4620808B2 (ja) | 突然変異上皮成長因子受容体を標的とする試薬および方法 | |
Hurwitz et al. | Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. | |
Fan et al. | Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies | |
EP0474727B1 (en) | Her2 extracellular domain | |
KR101477762B1 (ko) | 특이성 결합 단백질 및 용도 | |
US7648703B2 (en) | Combination of anti-EP-CAM antibody with a chemotherapeutic agent | |
US20140187756A1 (en) | Methods of preparing antibody-active agent conjugates | |
HU230586B1 (hu) | Anti-ErbB antitest/maytansinoid konjugátumok alkalmazása rákos betegségek kezelésére szolgáló gyógyszer előállítására | |
JP2002515511A (ja) | 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療 | |
JPH10136988A (ja) | 組換えシュードモナスエクソトキシン:低副作用の活性イムノトキシンの構造 | |
JP2001504326A (ja) | 抗ErbB2抗体 | |
US20150056216A1 (en) | Antibody combinations and use of same for treating cancer | |
CN111529717A (zh) | 抗体药物偶联物 | |
Sokolova et al. | Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency | |
JP2001521733A (ja) | ヒト上皮増殖因子とヒトアンギオゲニンの融合タンパク質およびその製造方法 | |
JP2020532523A (ja) | 抗egfr抗体薬物コンジュゲート(adc)及びその使用 | |
EP0739984A1 (en) | Bivalent polypeptides containing at least two domains | |
TWI433853B (zh) | 產生能避免介白素2與其受體結合之自體抗體的免疫治療調製劑及彼於治療癌症上之用途 | |
AU2005328131B2 (en) | Anticancer agent | |
CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
KR101215768B1 (ko) | p185neu - 암호화 DNA와 그의 치료 용도 | |
JP2020532543A (ja) | 抗egfr抗体薬物コンジュゲート(adc)及びその使用 | |
US20230097992A1 (en) | Bivalent egf fusion toxins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |